Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy ; volume:9 ; number:1 ; day:6 ; month:9 ; year:2016 ; pages:1-9 ; date:12.2016
Journal of hematology & oncology ; 9, Heft 1 (6.9.2016), 1-9, 12.2016
- Creator
-
Niewerth, Denise
- Contributor
-
Kaspers, Gertjan J. L.
Jansen, Gerrit
van Meerloo, Johan
Zweegman, Sonja
Jenkins, Gaye
Whitlock, James A.
Hunger, Stephen P.
Lu, Xiaomin
Alonzo, Todd A.
van de Ven, Peter M.
Horton, Terzah M.
Cloos, Jacqueline
SpringerLink (Online service)
- DOI
-
10.1186/s13045-016-0312-z
- URN
-
urn:nbn:de:1111-201610066958
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Niewerth, Denise
- Kaspers, Gertjan J. L.
- Jansen, Gerrit
- van Meerloo, Johan
- Zweegman, Sonja
- Jenkins, Gaye
- Whitlock, James A.
- Hunger, Stephen P.
- Lu, Xiaomin
- Alonzo, Todd A.
- van de Ven, Peter M.
- Horton, Terzah M.
- Cloos, Jacqueline
- SpringerLink (Online service)
Other Objects (12)
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
Testicular leukaemic infiltration in relapsed acute lymphoblastic leukaemia: a case report
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
Testicular leukaemic infiltration in relapsed acute lymphoblastic leukaemia: a case report
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
Testicular leukaemic infiltration in relapsed acute lymphoblastic leukaemia: a case report
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome